pPACK-SPIKE B.1.351 S1 Mutations (RBD+D614G) Lentivector Packaging Mix
Expand your understanding of SARS-CoV-2 variants with a packaging mix for lentivirus pseudotyped with the S1 spike protein found in B.1.351 (K417N, E484K, N501Y, and D614G)
- Based on SBI’s popular and highly cited pPACKH1 Packaging System
- Uses codon-optimized SARS-CoV-2 K417N, E484K, N501Y, D614G “S” protein in place of VSV-G envelope protein
- Ideal for vaccine and antiviral efficacy studies under BSL2 conditions
- Package any 3rd-generation lentivector reporter of your choice, including SBI’s popular LentiLabeler reporters
- Compare with our full range of pPACK-SPIKE S protein pseudotyped lentiviruses to better understand emerging variants
- Use with pPACK-BALD™, an envelope protein-free lentivector packaging system that is an ideal negative control
Overview
Safely study the spike protein from emerging SARS-CoV-2 variants
As potentially more transmissible variants of SARS-CoV-2 emerge, understanding how mutations in the spike protein impact SARS-CoV-2 behavior is critical. With the pPACK-SPIKE B.1.351 S1 Mutations (RBD + D614G) Lentivector Packaging Mix, you can safely characterize the SARS-CoV-2 S1 spike protein from the emerging South African lineage B.1.351 (also known as 501Y.V2)—K417N, E484K, N501Y, and D614G. Designed to efficiently package most third-generation lentivectors, the pPACK-SPIKE B.1.351 S1 Mutations (RBD + D614G) Lentivector Packaging Mix speeds and simplifies preparation of lentiviral particles pseudotyped with the SARS-CoV-2 K417N, E484K, N501Y, D614G spike glycoprotein, making it an ideal reagent for vaccine and antiviral drug discovery projects.
Based on SBI’s highly cited pPACKH1 packaging system but with a truncated SARS-CoV-2 K417N, E484K, N501Y, D614G Spike protein [1] replacing the standard VSV-G envelope protein, the pPACK-SPIKE B.1.351 S1 Mutations (RBD + D614G) Lentivector Packaging Mix consists of three plasmids that produce all of the structural and replication proteins needed to transcribe and package an RNA copy of an expression lentivector into recombinant, K417N, E484K, N501Y, D614G “Spike” pseudotyped lentiviral particles. As a result, you can conduct a range of SARS-CoV-2 studies under BSL-2 conditions, including neutralization assays, studies of virus interactions with host surface proteins, and the development of vaccines and therapeutics.
For added convenience we also offer pPACK-BALD™, an envelope protein-free lentivector packaging mix that can be used as a negative control for any pPACK-SPIKE study, or for creating lentivirus particles pseudotyped with the envelope protein of your choice.
- Based on SBI’s popular and highly cited pPACKH1 Packaging System
- Uses codon-optimized SARS-CoV-2 K417N, E484K, N501Y, D614G “S” protein in place of VSV-G envelope protein
- Ideal for vaccine and antiviral efficacy studies under BSL2 conditions
- Package any 3rd-generation lentivector reporter of your choice, including SBI’s popular LentiLabeler reporters
- Compare with our full range of pPACK-SPIKE S protein pseudotyped lentiviruses to better understand emerging variants
- Use with pPACK-BALD™, an envelope protein-free lentivector packaging system that is an ideal negative control
pPACK-SPIKE B.1.351 S1 Mutations (RBD + D614G) Lentivector Packaging Mix is available as stand-alone packaging mixes with sufficient plasmids for 10 reactions (standard size) or 25 reactions (XL), as well as in a convenient kit format that includes PureFection™ Transfection Reagent and PEG-it Virus Precipitation Solution.
See all of the available pPACK-SPIKE S protein variants:
Catalog Number | Product Description | Spike protein variant |
---|---|---|
CVD19-500A-1 | pPACK-SPIKE SARS-CoV-2 “S” Pseudotype Lentivector Packaging Mix | Original Wuhan-Hu-1 strain |
CVD19-530A-1 | pPACK-SPIKE™ D614G, SARS-CoV-2 “S” Pseudotype – D614G Mutant – Lentivector Packaging Mix | D614G Spike protein variant present in the dominant summer 2020 strain |
CVD19-560A-1 | pPACK-SPIKE N501Y, SARS-CoV-2 "S" Pseudotype - N501Y Mutant - Lentivector Packaging Mix | N501Y Spike protein variant present in mouse-adapted SARS-CoV-2 and used in mouse models of infection (Gu, H, et al. Science. 2020 Sep 25;369(6511):1603. PMCID: PMC7574913.) |
CVD19-580A-1 | pPACK-SPIKE B.1.351 RBD Mutations Lentivector Packaging Mix | Spike protein receptor binding domain mutations K417N, E484K, & N501Y from SARS-CoV-2 lineage B.1.153, also known as 501Y.V2 |
CVD19-600A-1 | pPACK-SPIKE B.1.351 S1 Mutations (RBD+D614G) Lentivector Packaging Mix | Spike protein mutations K417N, E484K, N501Y, & D614G from SARS-CoV-2 lineage B.1.153, also known as 501Y.V2 |
LV550A-1 | pPACK-BALD™ (Negative Control Packaging Mix) | An envelope protein-free negative control for pPACK-SPIKE |
References
- Ou X, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat. commun. 2020 Mar 27;11(1):1620. doi: 10.1038/s41467-020-15562-9. PMCID: PMC7100515.
Supporting Data
To see data generated using the pPACK-SPIKE with the S protein from the original Wuhan-Hu-1 strain, visit the pPACK-SPIKE page.